← Calendar
Readoutin 76d
Hoffmann-La Roche — Ranibizumab
Phase 3 primary completion: A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome).
- Date
- Feb 2027
- Type
- Readout
- Indication
- Neovascular Age-related Macular Degeneration (nAMD)
Source ↗Add to calendar
Get told when this date moves
The weekly brief is free. Pro adds reminders 7 days and 1 day before.
More from Hoffmann-La Roche
Mar2027
Readoutin 104d
Hoffmann-La Roche — AtezolizumabPhase 3 primary completion: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy.
Jan2027
Readoutin 45d
Hoffmann-La Roche — AfimkibartPhase 3 primary completion: A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis.
Nov2026
ReadoutIn window
Hoffmann-La Roche — AtezolizumabPhase 3 primary completion: A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A).